ClinicaliQ Trial Snapshot
- Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study — Recruiting • Rare Diseases • NCT06016946.
- What is being tested: This is a natural history study tracking disease progression in Friedreich ataxia patients over time across multiple international centers, rather than testing a specific intervention—the data will establish baseline progression patterns to inform future therapeutic development.
- Patient eligibility overview: The study enrolls individuals with confirmed Friedreich ataxia diagnoses globally; specific inclusion/exclusion criteria would typically encompass various disease stages to capture the full clinical spectrum from early to advanced disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Eligibility Snapshot
- : 1. Both males and females of any age
- Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia 3. Written informed consent provided 1. Informed consent must be obtained for all participants 2. For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable) 3. Persons who are not legally competent require the informed consent of their legally authorized representative
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.